NCT06822829 Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma
| NCT ID | NCT06822829 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Azienda USL Reggio Emilia - IRCCS |
| Condition | Diffuse Large B Cell Lymphoma (DLBCL) |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-08-19 |
| Primary Completion | 2025-10-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2024-08-19 with a primary completion date of 2025-10-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Most relapses of diffuse large B-cell lymphoma (DLBCL) occur as high-grade lymphoma within the first two years after diagnosis. Relapses as indolent lymphoma are rare events, and the true incidence of this phenomenon is unknown, since literature data are scarce/ and usually restricted to case reports. Analogously, reported treatment strategies are rather heterogeneous, since no standard of care is established and advanced age together with previous anthracycline exposure may narrow the therapeutic choice. The goal of this observational study is to assess epidemiological, clinical characteristics and survival of diffuse large b-cell lymphoma (DLBCL) relapsing as indolent lymphoma. More precisely, the study aims at identifying diagnostic and imaging features associated with relapse as indolent lymphoma and at evaluating disease response to selected therapies.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older at the time of diagnosis. * Previous diagnosis of diffuse large B-cell lymphoma with/without a discordant component of indolent B-cell lymphoma, or previous diagnosis of diffuse large B-cell lymphoma transformed from indolent B-cell lymphoma. * First-line treatment for diffuse large B-cell lymphoma. * Histologically documented relapse of indolent B-cell lymphoma, diagnosed between 2010 and 2020. * Availability of the histological report of the relapse. * Availability of clinical and laboratory data related to both the initial diagnosis and relapse. * Availability of follow-up data. * Consent to participate in the study and signing of the specific informed consent form (for living and/or contactable patients). Exclusion Criteria: \- None
Contact & Investigator
Maria Elena Nizzoli, MD
PRINCIPAL INVESTIGATOR
Azienda USL - IRCCS di Reggio Emilia
Frequently Asked Questions
Who can join the NCT06822829 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diffuse Large B Cell Lymphoma (DLBCL). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06822829 currently recruiting?
Yes, NCT06822829 is actively recruiting participants. Contact the research team at attilio.gennaro@ausl.re.it for enrollment information.
Where is the NCT06822829 trial being conducted?
This trial is being conducted at Reggio Emilia, Italy.
Who is sponsoring the NCT06822829 clinical trial?
NCT06822829 is sponsored by Azienda USL Reggio Emilia - IRCCS. The principal investigator is Maria Elena Nizzoli, MD at Azienda USL - IRCCS di Reggio Emilia. The trial plans to enroll 50 participants.